Search for drugs:
Typing the drug name to query
ATEZOLIZUMAB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- ADVERSE REACTIONS
- Cardiac Disorders: Arrhythmias, ejection fraction decreased, electrocardiogram QT prolonged
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
4
24088
Other ADRs
17334
38364253
Odds Ratio = 0.368
Drug Property Information
ATC Code(s):
- L01XC32 - atezolizumab
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:atezolizumab
Active Ingredient UNII:52CMI0WC3Y
Drugbank ID:DB11595
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection, solution
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.